[Click eStock] "Osteonic, Full-Scale Entry into the US Market"

On the 9th, KB Securities predicted that Osteonic would make a full-scale entry into overseas markets after receiving approval from the U.S. Food and Drug Administration (FDA) for its sports medicine product line.

Osteonic is an orthopedic implant company. In 2020, it signed an exclusive OEM (Original Equipment Manufacturer) and ODM (Original Design Manufacturer) supply contract with Zimmer Biomet.

Researcher Han Jeyoon of KB Securities explained, "From the first year of entering the U.S. market, Osteonic can utilize the distribution network and sales power of the world's second-largest medical device company," adding, "Osteonic's sports medicine product line indirectly proves its competitiveness through high growth in existing distribution channels."

He continued, "It is positive that both product competitiveness and distribution networks are in place," and added, "With Zimmer-related U.S. sales occurring, the corporate value will also be re-evaluated."

The researcher analyzed, "It is expected to receive approval in China this year," and "the approval process is underway." He emphasized, "Since most receive final results within three years, results will be confirmed in the first half of this year," and stated, "Based on clear product competitiveness, the representative product line, which is rapidly growing in existing channels, will be supplied to China."

This content was produced with the assistance of AI translation services.